James Hamilton, MD

Professional Titles

• Director of Hepatology
• Interim Director, Division of Gastroenterology and Hepatology

Primary Academic Title

Associate Professor of Medicine

Background

Centers and Institutes

• Comprehensive Transplant Center
• Healthful Eating, Activity & Weight Program

Clinical Trials Summary

A Phase 3, Double-Blind Randomized, Long-term, Placebo-controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid (OCA) in subjects with Non-Alcoholic Steatohepatitis (REGENERATE)

A Phase 2, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

Sofusbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant

A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)

Find a Clinical Trial

Additional Academic Titles

Associate Professor of Physiology, Pharmacology and Therapeutics

Contact for Research Inquiries

720 Rutland Ave
Ross 921
Baltimore, MD 21205

Research Interests

Early detection biomarker discovery for hepatocellular carcinoma, Wilson Disease: Copper homeostasis and regulation of lipid metabolism and liver injury. Pathogenesis of Liver fibrosis and cancer

Lab Website

James Hamilton Lab

• The main research interests of the James Hamilton Lab are the molecular pathogenesis of hepatocellular carcinoma and the development of molecular markers to help diagnose and manage cancer of the liver. In addition, we are investigating biomarkers for early diagnosis, prognosis and response to various treatment modalities. Results of this study will provide a molecular classification of HCC and allow us to identify targets for chemoprevention and treatment. Specifically, we extract genomic DNA and total RNA from liver tissues and use this genetic material for methylation-specific PCR (MSP), cDNA microarray, microRNA microarray and genomic DNA methylation array experiments.

Selected Publications

• Hamilton JP, Koganti L, Muchenditsi A, Pendyala VS, Huso D, Hankin J, Murphy RC, Huster D, Merle U, Mangels C, Yang N, Potter JJ, Mezey E, Lutsenko S. Activation of LXR/RXR Pathway Ameliorates Liver disease in ATP7b-/- (Wilson disease) mice. Hepatology 2016; 63(6): 1828-41. PMID: 26679751

• Hamilton JP, Potter JJ, Koganti L, Meltzer SJ, Mezey E. Effects of Vitamin D stimulation of Thioredoxin Interacting Protein in hepatocellular carcinoma. Hepatol Res. 2014; 44(13): 1357-66. PMID: 24451003

• Karthikeyan S, Potter JJ, Geschwind JF, Sur S, Hamilton JP, Vogelstein B, Kinzler KW, Mezey E, Gaganpathy-Kanniappan S. Deregulation of energy Metabolism Promotes Antfibrotic Effects in Human Hepatic Stellate Cells and Prevents Liver Fibrosis in a Mouse Model. Biochem Biophys Res Comm 2016; 469(3): 463-9. PMID: 26525850

• Oh Y, Park O, Swierczewska M, Hamilton JP, Park JS, Kim TH, Lim SH, Eom H, Jo DG, Lee CE, Kechrid R, Mastorakos P, Zhang C, Hahn SK, Jeon OC, Byun Y, Km K, Hanes J, Lee KC, Pomper MG, Gao B, Lee S. Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating hepatic stellate cells. Hepatology 2016; 64(1): 209-23. PMID: 26710118

Honors

• Research Fellowship, NRSA
• Top Doctor, Baltimore Magazine, 1/1/20
• Top Doctor, Baltimore Magazine, 1/1/19
• Top Doctor, Baltimore Magazine, 1/1/18

Memberships

• AASLD
• AGA